Eli Lilly

View All

Lilly moves ahead; Authorities raid; Bristol-Myers, AZ in legal; PhRMA expected to weed out

Lilly moves forward with biologics plant expansion in Ireland Eli Lilly has confirmed that it will move forward with plans to add a manufacturing line at its site in Kindsdale, County Cork in Ireland. The construction might begin in coming months and commissioning will begin in 2019. The expansion is expected to add...

Find More

Therapeutics
Letter for AstraZeneca; Patheon on API plant; Sanofi, Regeneron’s Dupixent; Cerulean Pharma and Daré Bioscience enter into deal; Lilly on price hikes

AstraZeneca slapped with second Complete Response Letter Having a potential blockbuster sidelined because of manufacturing issues is bad enough, but AstraZeneca has now had that experience twice—both times receiving a complete response letter from the FDA. For a second time, AstraZeneca has received a complete respo...

Find More

Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat

Glaxo replaces ViiV Healthcare chief as executive shuffle continues The executive exodus at GlaxoSmithKline is continuing—and so is the rise of women to the company’s top ranks. The British pharma giant announced that Dominique Limet, head of HIV unit ViiV Healthcare, would step down at the end of March 2017—the sam...

Find More

Delveinsight
Oncology Therapeutics Making Big in Coming Years

The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of t...

Find More